Published in World J Gastroenterol on June 14, 2014
Pathological characterization and morphometric analysis of hepatic lesions in SHRSP5/Dmcr, an experimental non-alcoholic steatohepatitis model, induced by high-fat and high-cholesterol diet. Int J Exp Pathol (2016) 0.75
Molecular imaging of aberrant crypt foci in the human colon targeting glutathione S-transferase P1-1. Sci Rep (2017) 0.75
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med (2003) 8.47
Induction of immunological tolerance by porcine liver allografts. Nature (1969) 5.89
Weaning of immunosuppression in living donor liver transplant recipients. Transplantation (2001) 2.18
The liver as a site of T-cell apoptosis: graveyard, or killing field? Immunol Rev (2000) 2.13
Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl (2003) 2.01
The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology (2003) 1.64
Chemokines in liver inflammation and fibrosis. Front Biosci (2002) 1.63
Weaning of immunosuppression in long-term liver transplant recipients. Transplantation (1995) 1.59
Weaning of immunosuppression in liver transplant recipients. Transplantation (1997) 1.57
Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation (1995) 1.53
Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. Am J Pathol (2003) 1.50
Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology (2009) 1.48
Effects of liver-derived dendritic cell progenitors on Th1- and Th2-like cytokine responses in vitro and in vivo. J Immunol (2000) 1.47
Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol (2006) 1.40
Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA (2012) 1.33
Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol (2006) 1.28
Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology (1994) 1.14
Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation (2003) 1.08
Tolerance: is it worth the risk? Transplantation (2005) 1.03
The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant (2005) 1.01
Orthotopic liver allografts in the rat. The influence of strain combination on the fate of the graft. Transplantation (1984) 1.00
Clinical tolerance following liver transplantation: long term results and future prospects. Transpl Immunol (2006) 0.91
Clinical trials of transplant tolerance: slow but steady progress. Am J Transplant (2003) 0.91
Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation (2007) 0.90
Incidence and outcome of de novo malignancies after liver transplantation. Transplant Proc (1999) 0.89
Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation (2009) 0.87
Late protocol liver biopsies in the liver allograft: a neglected investigation? Liver Transpl (2009) 0.86
Primary immunosuppression with tacrolimus after liver transplantation: 12-years follow-up. Int Immunopharmacol (2005) 0.86
Operational tolerance in clinical liver transplantation: emerging developments. Transpl Immunol (2006) 0.85
Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid. Transplantation (2007) 0.80
Inhibition of allogenic T-cell cytotoxicity by hepatic stellate cell via CD4⁺ CD25⁺ Foxp3⁺ regulatory T cells in vitro. Transplant Proc (2012) 0.78
Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in non-transplanted patients with chronic hepatitis C. Liver Transpl (2007) 0.77